Pegaspargase

CHEMBL2108546 Phase 4 Disetujui Enzyme

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This enzyme-based cancer medication treats acute lymphoblastic leukemia by depleting asparagine that leukemia cells need.

Area Terapeutik

Non-Small Cell Lung Cancer Lymphoma Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This enzyme-based cancer medication treats acute lymphoblastic leukemia by depleting asparagine that leukemia cells need.

Yes, Pegaspargase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108546. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Mencari informasi yang ramah bagi pasien?

Pegaspargase di PillFYI

Data Cepat

Sinonim: 2

Tautan Eksternal

ChEMBL CHEMBL2108546

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.